陈永军; 赵波; 陈文瑾; 陈记赛; 蔡小勇

doi:10.3760/cma.j.cn421213-20221122-01374

点赞 0
分享 0
收藏 0
纠错

• 临床研究 •

微小RNA-92a在结直肠癌患者血清、肿瘤组织和粪便中的表达及其临床意义

中华实验外科杂志, 2023,40(6) : 1135-1138. DOI: 10.3760/cma.j.cn421213-20221122-01374

摘要

目的

分析血清、肿瘤组织和粪便样本中微小RNA(miRNA，miR)-92a在结直肠癌患者中的表达及意义。

方法

选取45例结直肠癌患者作为实验组，同期45例健康体检人群为对照组，分别检测两组血清、肿瘤与癌旁组织、粪便样本中miR-92a的表达量，通过实时定量反转录聚合酶链反应(RT-qPCR)定量，对表达量结果进行差异统计学分析，临床特征与肿瘤样本的表达量的分析，临床特征与miRNA表达量相关性。

结果

miR-92a在肿瘤组与正常对照对比表达有统计学意义，肿瘤组表达均高于正常组，其中肿瘤组织中的miRNA表达量明显高于血液和粪便(血液样本中：t＝28.88，P<0.001，肿瘤组织样本：t＝22.78，P<0.001，粪便样本：t＝15.97，P<0.001)。血清、肿瘤组织与淋巴结转移、浸润深度、TNM分期和分化程度表达呈正相关，粪便样本仅与分化程度正相关，血液样本比淋巴结转移(r＝0.674)，血液样本比TMN分期(r＝0.691)，血液样本比浸润深度(r＝0.715)，血液样本比分化程度(r＝0.648)，肿瘤组织比淋巴结转移(r＝0.494)，肿瘤组织比TMN分期r＝0.526，肿瘤组织比浸润深度(r＝0.486)，肿瘤组织比分化程度(r＝0.545)，粪便组织比分化程度(r＝0.495)。粪便组织比淋巴结转移(r＝0.258)，粪便组织比TMN分期(r＝0.226)，粪便组织比浸润深度(r＝0.341，P>0.05)。

结论

粪便、血浆、组织样本中可检测的miR-92a作为临床生物标志物具有可行性。

引用本文: 陈永军, 赵波, 陈文瑾, 等. 微小RNA-92a在结直肠癌患者血清、肿瘤组织和粪便中的表达及其临床意义 [J] . 中华实验外科杂志, 2023, 40(6) : 1135-1138. DOI: 10.3760/cma.j.cn421213-20221122-01374.

参考文献导出: Endnote NoteExpress RefWorks NoteFirst 医学文献王

扫描看全文

正文

作者信息

基金 0 关键词 0

English Abstract

阅读 0 评论 0

相关资源

引用 | 论文 | 视频

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

研究表明，微小RNA(microRNA，miRNA，miR)的调控作用是结直肠癌(colorectal cancer，CRC)的重要推动力，它不仅能够促进CRC的启动，还能够推动CRC的发展^[1]。许多miRNA已被发现为CRC中细胞凋亡的启动子或细胞凋亡的抑制剂。除了抑制癌症细胞增殖和激活凋亡外，miRNA在结直肠癌中还起到抑癌作用。研究结果表明，miR-92a是一种致癌基因，miR-92a是CRC干细胞起源的关键因素^[2]，它尚未在癌症调控方面进行广泛研究，本研究旨在探讨miR-92a在CRC患者血清及粪便的表达及预后预测。

贡献者信息

陈永军

广西医科大学第二附属医院普通外科，南宁　530007

赵波

广西医科大学第二附属医院普通外科，南宁　530007

陈文瑾

广西医科大学第二附属医院普通外科，南宁　530007

陈记赛

广西医科大学第二附属医院普通外科，南宁　530007

蔡小勇

广西医科大学第二附属医院普通外科，南宁　530007

通信作者

蔡小勇

广西医科大学第二附属医院普通外科，南宁　530007

Email：cxy0771@163.com

关键词

结直肠癌; 微小RNA-92a; 粪便; 血液; 肿瘤组织;

基金项目

广西壮族自治区卫生健康委员会自筹经费科研课题（Z-A20220579）

广西医疗卫生重点培育学科建设项目（2021063）

广西临床重点专科建设项目（2022184）

利益冲突

所有作者均声明不存在利益冲突

历史

出版日期：2023-06-08

收稿日期：2022-11-22

Clinical Research

Expression and significance of microRNA-92a in serum, tumor tissues and stool samples in colorectal cancer patients

Chen Yongjun, Zhao Bo, Chen Wenjin, Chen Jisai, Cai Xiaoyong

Published 2023-06-08

Cite as Chin J Exp Surg, 2023, 40(6): 1135-1138. DOI: 10.3760/cma.j.cn421213-20221122-01374

Abstract

Objective

To analyze the expression and significance of microRNA (miRNA, miR)-92a in serum, tumor tissues and stool samples in colorectal cancer patients.

Methods

Totally, 45 patients with colorectal cancer were selected as the experimental group, and 45 volunteers given the healthy physical examination served as the control group during the same period. The expression of miR-92a in serum, tumor and paraneoplastic tissues, and stool samples was detected in both groups, and the expression results were quantified by real-time quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR). The statistical analysis of differences between clinical characteristics and expression of tumor samples, and the analysis of correlation between clinical characteristics and miRNA expression were carried out.

Results

There was significant difference in the dimiR-92a expression between tumor group and normal controls, and the expression of miR-92a in the tumor group was higher than that in the normal group. The miRNA expression in tumor tissues was significantly higher than that in blood and stool samples (t=28.88, P<0.001 in blood samples; t=22.78, P<0.001 in tumor tissue samples; t=15.97, P< 0.001). The expression of miRNAA in serum and tumor tissue was positively correlated with lymph node metastasis, depth of infiltration, TNM stage and degree of differentiation, and only with degree of differentiation in fecal samples [r=0.674 for blood samples vs. lymph node metastasis; r=0.691 for blood samples vs. TMN stage; r=0.715 for blood samples vs. depth of infiltration; r=0.648 for blood samples vs. degree of differentiation; r=0.494, tumor tissue vs. lymph node metastasis; r=0.526, tumor tissue vs. TMN stage; r=0.486, tumor tissue vs. depth of infiltration; r=0.545, tumor tissue vs. degree of differentiation; r=0.495, fecal tissue vs. degree of differentiation (P<0.05); fecal tissue vs. lymph node metastasis, r=0.258, fecal tissue vs. TMN staging, r=0.226, and fecal tissue vs. depth of infiltration r=0.341 (P>0.05).

Conclusion

Detectable miR-92a in fecal, plasma, and tissue samples is feasible as a clinical biomarker.

Key words:

Colorectal cancer; MicroRNA-92a; Stool; Blood; Tumor tissue

Contributor Information

Chen Yongjun